文献速递脊柱关节炎类风湿关节炎

司库奇尤单抗治疗银屑病关节炎伴中轴表现:MAXIMISE试验结果

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.
PubMed 文献 · Ann Rheum Dis · 2020-12-17

MAXIMISE是一项3b期双盲安慰剂对照52周试验,纳入167例、165例和166例分别接受司库奇尤单抗300mg、150mg和安慰剂治疗的活动性银屑病关节炎伴中轴表现且NSAIDs应答不足的患者。第12周时,司库奇尤单抗300mg和150mg组ASAS20应答率分别为63%和66%,显著高于安慰剂组的31%。

要点

  • 司库奇尤单抗300mg和150mg均显著改善银屑病关节炎患者的中轴症状。
  • 第12周ASAS20应答率:300mg组63%、150mg组66%,安慰剂组31%。
  • 至少两种NSAIDs应答不足且BASDAI≥4、脊柱疼痛VAS≥40/100的患者可考虑使用。

核心结论

  • 司库奇尤单抗300mg和150mg较安慰剂显著改善银屑病关节炎伴中轴表现且NSAIDs应答不足患者的体征和症状。

研究设计与样本

  • 3b期双盲安慰剂对照多中心52周试验,纳入年龄≥18岁、符合CASPAR标准、脊柱疼痛VAS≥40/100且BASDAI≥4、至少两种NSAIDs应答不足的银屑病关节炎患者。
  • 患者按1:1:1随机分配至司库奇尤单抗300mg、150mg或安慰剂,每周给药4周后每4周给药;第12周时安慰剂组患者重新随机分配至司库奇尤单抗300mg或150mg。
  • 样本量:司库奇尤单抗300mg组167例,150mg组165例,安慰剂组166例。

主要发现

  • 第12周司库奇尤单抗300mg和150mg组ASAS20应答率分别为63%和66%,安慰剂组为31%。
  • 司库奇尤单抗300mg和150mg对比安慰剂的OR(95%CI)分别为3.8(2.4-6.1)和4.4(2.7-7.0),p<0.0001。

关键数值与推荐

  • 主要终点为第12周司库奇尤单抗300mg组的ASAS20应答。
  • ASAS20应答率:300mg组63%、150mg组66%、安慰剂组31%。
  • OR(95%CI):300mg vs 安慰剂3.8(2.4-6.1),150mg vs 安慰剂4.4(2.7-7.0),p<0.0001。

临床怎么用

  • 对于银屑病关节炎伴中轴表现且至少两种NSAIDs应答不足的患者,司库奇尤单抗300mg或150mg可作为改善中轴症状的治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: MAXIMISE (Managing AXIal Manifestations in psorIatic arthritis with SEcukinumab) trial was designed to evaluate the efficacy of secukinumab in the management of axial manifestations of psoriatic arthritis (PsA). METHODS: This phase 3b, double-blind, placebo-controlled, multi-centre 52-week trial included patients (≥18 years) diagnosed with PsA and classified by ClASsification criteria for Psoriatic Arthritis (CASPAR) criteria, with spinal pain Visual Analogue Score ≥40/100 and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≥4 despite use of at least two non-steroidal anti-inflammatory drugs (NSAIDs). Patients were randomised (1:1:1) to secukinumab 300 mg, secukinumab 150 mg or placebo weekly for 4 weeks and every 4 weeks thereafter. At week 12, placebo patients were re-randomised to secukinumab 300/150 mg. Primary endpoint was ASAS20 (Assessment of SpondyloArthritis international Society) response with secukinumab 300 mg at week 12. RESULTS: Patients were randomly assigned; 167 to secukinumab 300 mg, 165 to secukinumab 150 mg and 166 to placebo. Secukinumab 300 mg and 150 mg significantly improved ASAS20 response versus placebo at week 12 (63% and 66% vs 31% placebo). The OR (95% CI) comparing secukinumab 300 mg and 150 mg versus placebo, using a logistic regression model after multiple imputation, was 3.8 (2.4 and 6.1) and 4.4 (2.7 and 7.0; p<0.0001). CONCLUSIONS: Secukinumab 300 mg and 150 mg provided significant improvement in signs and symptoms of axial disease compared with placebo in patients with PsA and axial manifestations with inadequate response to NSAIDs. TRIAL REGISTRATION NUMBER: NCT02721966.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2020. PMID: 33334727. doi:10.1136/annrheumdis-2020-218808

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。